Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
But a 24% remission rate is still enough to get the project before the US regulator, analysts reckon.